Vendor Intelligence Report: XTP

Published 2 Jul 2026. 16-page investigative report on who is behind XTP: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

XTP’s quantified record is narrow, not nonexistent. Across 5 Finnrick lab tests, XTP records 4 pass / 1 fail for an overall pass rate of 80%. The dataset covers Retatrutide only, making XTP a plausible but not top-tier Retatrutide option for buyers who verify exact batches; it does not validate Tirzepatide, KLOW, or the wider catalog. The report also shows how the read changes under stricter grading thresholds.

The strongest safety concern sits outside Finnrick’s Retatrutide row. A May 2026 forum-described independent testing incident reported a Tirzepatide product with no detectable Tirzepatide and KLOW testing as GHK-CU only. The dispute also exposed a remediation problem: XTP reportedly resisted reimbursing testing costs until public pressure changed the outcome.

The ownership and operating trail remains only partly visible. XTP presents as Xi'an Taiye Chemical Co., Ltd. in Xi'an, but the investigation did not verify that English-name entity in the named Chinese registry searches. xtpep.com traces to an April 2025 HOSTINGER operations, UAB registration with privacy protection and Lithuanian registrant-country data. Forum operations moved from Bella.xtp, later banned without public explanation in the supplied record, to Emma33; XTP’s “Janoshik Testing Synchronized” claim also lacked a public Janoshik result trail.

Inside the full report:

  • Appendix A Finnrick lab table and methodology-divergence charts for the Retatrutide dataset
  • WHOIS exhibits for xtpep.com and the privacy-protected Lithuanian registrar trail
  • GLP-1 Forum timeline covering Bella.xtp, Emma33, warehouse announcements, and the account ban
  • Claim check on “Janoshik Testing Synchronized” against public Janoshik search results
  • Product-identity incident analysis for Tirzepatide, KLOW, and the reimbursement dispute
  • CBP Cincinnati seizure context with explicit attribution limits

Risk assessment

  • Tirzepatide and KLOW product-identity risk — high: A May 2026 forum-described testing incident reported Tirzepatide with no detectable Tirzepatide and KLOW testing as GHK-CU only.
  • Retatrutide batch-reliability risk — medium: Finnrick’s current XTP Retatrutide record is 5 tests with 4 pass / 1 fail and a 79.14% rating, making batch-specific verification important.
  • Verification-transparency risk — medium: The claimed operating entity is not verified in named registry searches, the domain is privacy-registered, Janoshik public search found zero XTP results, and Bella.xtp was banned without a public explanation.
  • Complaint-remediation risk — medium: Forum materials state XTP initially resisted the customer’s $900 testing-cost reimbursement and paid only after threatened public disclosure.